Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.34 |
| ▸ | PDXK | O00764 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.33 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | NQO2 | P16083 | 1/20 | 0.31 |
| ▸ | FYN | P06241 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16421188 | 0.81 | PARP1 (0.33) | KDM4ETHRB | |
| SCHEMBL336161 | 0.78 | SHBG (0.41) | HSD17B10KDM4EALDH1A1HPGDLMNA | |
| SCHEMBL1705316 | 0.77 | KDM4E (0.42) | HSD17B10KDM4EALDH1A1HPGDLMNA | |
| SCHEMBL31717889 | 0.77 | KDM4E (0.42) | HSD17B10KDM4EALDH1A1HPGDLMNA | |
| SCHEMBL12042082 | 0.76 | KDM4E (0.40) | HSD17B10KDM4ELMNAMAOADYRK1A | |
| SCHEMBL18900157 | 0.75 | KDM4E (0.37) | HSD17B10KDM4EALDH1A1HPGDLMNA | |
| SCHEMBL413400 | 0.75 | RXRA (0.35) | HSD17B10ALOX15TSHRRECQLACHE | |
| SCHEMBL335538 | 0.75 | VRK1 (0.38) | HSD17B10KDM4EALDH1A1HPGDLMNA | |
| SCHEMBL335605 | 0.75 | RECQL (0.39) | HSD17B10KDM4EALDH1A1HPGDLMNA | |
| SCHEMBL487778 | 0.75 | CYP11B1 (0.50) | ALDH1A1PDXKRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260138991-A1 | SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES | MOMA THERAPEUTICS INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-12600728-B2 | Interleukin-17 inhibitors | NOVARTIS AG (CH) | 2026-04-14 | — | — | US | disclosed |
| EP-4178620-B1 | PLASMA KALLIKREIN INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2026-04-01 | — | — | EP | disclosed |
| EP-4705298-A2 | SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES | Moma Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| US-12559508-B2 | Semi-saturated bicyclic derivatives and related uses | MOMA THERAPEUTICS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-12528786-B2 | Plasma kallikrein inhibitors | MERCK SHARP & DOHME LLC (US) | 2026-01-20 | — | — | US | disclosed |
| US-20250230171-A1 | SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES | MOMA THERAPEUTICS, INC. | 2025-07-17 | — | — | US | disclosed |
| WO-2024211836-A2 | SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES | MOMA THERAPEUTICS, INC. (US) | 2024-10-10 | — | — | WO | disclosed |
| US-20230391782-A1 | INTERLEUKIN-17 INHIBITORS | NOVARTIS AG (CH) | 2023-12-07 | — | — | US | disclosed |
| US-20230348428-A1 | PLASMA KALLIKREIN INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-11-02 | — | — | US | disclosed |
| CN-102105473-A | Tricyclic nitrogen containing compounds and their use as antibacterials | GLAXO GROUP LTD | 2011-06-22 | — | — | CN | disclosed |
| EP-2300476-A1 | TRICYCLIC NITROGEN CONTAINING COMPOUNDS AND THEIR USE AS ANTIBACTERIALS | Glaxo Group Limited (GB) | 2011-03-30 | — | — | EP | disclosed |
| EP-2238135-A1 | NAPHTHYRIDIN-2(1H) -ONE COMPOUNDS USEFUL AS ANTIBACTERIALS | Glaxo Group Limited (GB) | 2010-10-13 | — | — | EP | disclosed |
| US-20090306089-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2009-12-10 | — | — | US | disclosed |
| US-20090306089-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2009-12-10 | — | — | US | disclosed |
| US-20090306089-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2009-12-10 | — | — | US | disclosed |
| WO-2009141398-A1 | TRICYCLIC NITROGEN CONTAINING COMPOUNDS AND THEIR USE AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2009-11-26 | — | — | WO | disclosed |
| WO-2009141398-A1 | TRICYCLIC NITROGEN CONTAINING COMPOUNDS AND THEIR USE AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2009-11-26 | — | — | WO | disclosed |
| WO-2009090222-A1 | NAPHTHYRIDIN-2(1H) -ONE COMPOUNDS USEFUL AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2009-07-23 | — | — | WO | disclosed |
| WO-2009090222-A1 | NAPHTHYRIDIN-2(1H) -ONE COMPOUNDS USEFUL AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2009-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230391782-A1 | INTERLEUKIN-17 INHIBITORS | IL17A, IL2, IL18 | HSD17B10 307/4885KDM4E 3144/4885ALDH1A1 287/4885 |
| US-20230348428-A1 | PLASMA KALLIKREIN INHIBITORS | KLKB1, SERPINE1, KLK5 | HSD17B10 1481/4885KDM4E 1129/4885ALDH1A1 1683/4885 |
| US-20250230171-A1 | SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES | POLQ, POLB, POLK | HSD17B10 460/4885KDM4E 2459/4885ALDH1A1 1052/4885 |
| US-20260138991-A1 | SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES | POLA1, SUB1, CTDSP1 | HSD17B10 475/4885KDM4E 4515/4885ALDH1A1 840/4885 |
| US-12528786-B2 | Plasma kallikrein inhibitors | CFH, KLKB1, SERPINH1 | HSD17B10 1467/4885KDM4E 998/4885ALDH1A1 3480/4885 |
| US-12559508-B2 | Semi-saturated bicyclic derivatives and related uses | POLA1, CTDSP1, SUB1 | HSD17B10 456/4885KDM4E 4522/4885ALDH1A1 589/4885 |
| US-20090306089-A1 | COMPOUNDS | SDHA, NQO1, SDHB | HSD17B10 565/4885KDM4E 4508/4885ALDH1A1 612/4885 |
| US-12600728-B2 | Interleukin-17 inhibitors | IL17A, IL2, IL1B | HSD17B10 1106/4885KDM4E 2847/4885ALDH1A1 958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.